Abstract:OBJECTIVE:To study the possibility of curing chronic myeloid leukemia with autogeneic hemopoietic stem cell transplantation in patients with negative Philadelphia (Ph) chromosome induced by imatinib mesylate (STI 571) treatment. METHODS:Two patients with chronic myeloid leukemia in chronic phase, who had 90% Ph chromosome-positive cells and bcr/abl fusion gene-positive cells as shown by interphase fluorescence in situ hybridization (I-FISH), failed to respond favorably to interferon-alpha therapy in the treatment courses of 7 and 8 months, respectively. Treatment with STI 571 at a daily dose of 300 to 400 mg for 5 months to 8 months was subsequently implemented, after which the Ph chromosome and bcr/abl fusion genes became normal in detection for 3 times. Peripheral blood haemopoietic stem cell mobilization was then initiated by intravenous injection of cytarabine (2.0 g/d) for 3 days, etoposide (0.2 g/d) for 3 d and cyclophosphamide (1.0 g/d) for one day. When the white blood cell was below 1.0x10(9)/L, the G-CSF (300 microg/d) was administered subcutaneously for 5 or 6 d, and the peripheral blood mononuclear cells were collected by CS3000 Plus blood cell separator. The percentage of bcr/abl fusion gene-positive cells among CD34(9) cells enriched by MiniMAC ranged from 11% to 14%. After 3 or 4 weeks, the patients received total body irradiation at 9 Gy given in 2 fractions, with intravenous injection of cyclophosphamide (60 mg/kg daily) and etoposide (300 mg/d) for 2 d. On the day of transplantation, the collected mononuclear cells were 4.17x10(8)/kg and 3.9x10(8)/kg, with CD34(+)/ cells reaching 4.89x10(6)/kg.b.w and 4.89x10(6)/kg. CsA was also used since day -1 to day +13 of the transplantation for prevention of graft-versus-host disease. G-CSF was administrated daily at the dose of 300 microg subcutaneously from day +3 to +12. RESULTS:After the transplantation, the absolute neutrophil count (ANC) took a mean of 11 d to exceed 0.5x10(9)/L in these two patients, and 19 and 21 d, respectively, were needed for the platelet count to exceed 20x10(9)/L. The two patients showed cytogenetic relapse at 120 and 300 d after the transplantation, respectively. CONCLUSION:Autogeneic peripheral blood stem cells transplantation after Ph chromosome is negative in patients with chronic myeloid leukemia, who receive STI 571 treatment, may also relapse, and more radical elimination of Ph chromosome-positive cells is needed.

Co-existence of Isodicentric Ph Chromosomes and the Three-Way Ph Chromosome Variant T(3;9;22)(p21;q34;q11) in a Rare Case of Chronic Myeloid Leukemia

Characteristics and Outcome of Chromosomal Abnormalities in Ph Negative Cells of Chronic Myelogenous Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia

[Cytogenetic and Molecular Analysis of 1193 Cases with Chronic Myeloid Leukemia].

Three-way Philadelphia Translocation [t(46, XX, t(9;22;16) (q34;q11.2;q24)] in Chronic Myeloid Leukemia: A Report of Two Cases with Review of the Literature

[Evolvement of a Five-Way Translocation T(5;9;22;6;17) from a Four-Way Philadelphia Translocation T(5;9;22;6) in a Rare Case of Chronic Myeloid Leukemia].

Extramedullary blast crisis of CD 34 + CD 38-leukemia stem cells in chronic myeloid leukemia resistant to tyrosine kinase inhibitors : a report of two cases

A Rare Case of X-Linked Four-Way Philadelphia Chromosome Translocation with Therapeutic Challenges and Clonal Evolution

The first case of six-way complex translocation of t(4;7;9;22;8;14) in a patient with chronic myeloid leukemia

Chronic Myeloid Leukemia with a Rare Philadelphia Chromosome Variant Involving Chromosome 16

Novel Four-Way Variant Translocation, t(1;9;22;16)(q21;q34;q11.2;q24), in a Patient with Chronic Myeloid Leukemia

Does presence of complex translocations involving BCR::ABL1 in chronic myeloid leukemia affect the response rate to tyrosine kinase inhibitors? A systematic review of the literature

[Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].

[Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].

Clonal Evolution Analyses of a Chronic Myeloid Leukemia Patient with Hematopoietic Stem Cell Transplantation Based on Deep Sequencing

Laboratory Study on A Rare Case of Chronic Myeloid Leukemia with Ins(22;9)t(9;13)and Ph-negative

Chromosomal Rearrangement Involving 11q23 Locus in Chronic Myelogenous Leukemia: a Rare Phenomenon Frequently Associated with Disease Progression and Poor Prognosis

A Novel Three-Way Ph Variant T(8;9;22) in Adult Acute Lymphoblastic Leukemia.

De Nove Philadelphia Chromosome-Positive Myelodysplastic Syndromes with Complex Karyotype and P230 BCR::ABL Fusion Transcript: a Case Report with a Literature Review

[Autogeneic peripheral blood hemopoietic stem cell transplantation for chronic myeloid leukemia with imatinib mesylate-induced negative Philadelphia chromosome].

De Nove Philadelphia Chromosome-Positive Myelodysplastic Syndromes with Complex Karyotype and P230 BCR::ABL Fusion Transcript: a Case Report with a Literature Review.